We propose to 1) Determine the origin of SV40-like sequences in human tumors; 2) Investigate if these viral sequences contribute to carcinogenesis; 3) Study if the expression of viral sequences can be used to develop new diagnostic approaches for mesothelioma and osteosarcoma patients. We will investigate the possible role of SV40-like DNA sequences in the development of human mesotheliomas and osteosarcomas. We will sequence, by PCR, the entire viral genome present in mesotheliomas and in osteosarcomas to determine how much of the viral genome is present in these human tumors and whether it is identical to the SV40 genome or mutated. We will attempt to isolate and sequence the SV40-like viruses from human mesotheliomas and osteosarcomas by transfecting DNAs from these tumors into permissive CV1 monkey cells. Next, we will investigate human biopsies by PCR, Northern and Western blot experiments, and immunohistochemistry, to determine if the SV40-like antigen (Tag) produced in human mesotheliomas binds and inactivates the cellular tumor suppressor proteins known to bind Tag in tissue culture: p53, Rb, pRb2, p107, p300. In addition, we will investigate by immunoperoxidase and Western blot experiments if the high level of c-fos expression we found in poor-risk osteosarcoma patients are induced by SV40-like in these tumors. Because SV40 small t antigen (tag) induces -fos in monkey cells in culture, we will transfect tag into human osteosarcoma cells in culture to test if tag can induce c-fos expression also in these cells. We will also investigate if the presence of SV40-like sequences in malignant mesothelioma cells can represent a useful marker for the pathologist for confirming, using PCR amplification, the often difficult morphologic diagnosis of mesothelioma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA077220-04
Application #
6172977
Study Section
Chemical Pathology Study Section (CPA)
Program Officer
Wong, May
Project Start
1997-08-01
Project End
2002-07-31
Budget Start
2000-08-01
Budget End
2001-07-31
Support Year
4
Fiscal Year
2000
Total Cost
$108,500
Indirect Cost
Name
Loyola University Chicago
Department
Pathology
Type
Schools of Medicine
DUNS #
791277940
City
Maywood
State
IL
Country
United States
Zip Code
60153
Carbone, Michele; Kratzke, Robert A; Testa, Joseph R (2002) The pathogenesis of mesothelioma. Semin Oncol 29:2-17
Rizzo, P; Matker, C; Powers, A et al. (2001) No evidence of HIV and SIV sequences in two separate lots of polio vaccines used in the first U.S. polio vaccine campaign. Virology 287:13-7
Roushdy-Hammady, I; Siegel, J; Emri, S et al. (2001) Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 357:444-5
Rizzo, P; Bocchetta, M; Powers, A et al. (2001) SV40 and the pathogenesis of mesothelioma. Semin Cancer Biol 11:63-71
Bocchetta, M; Di Resta, I; Powers, A et al. (2000) Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci U S A 97:10214-9
Hirvonen, A; Mattson, K; Karjalainen, A et al. (1999) Simian virus 40 (SV40)-like DNA sequences not detectable in finnish mesothelioma patients not exposed to SV40-contaminated polio vaccines. Mol Carcinog 26:93-9
Carbone, M (1999) Simian virus 40 and human tumors: It is time to study mechanisms. J Cell Biochem 76:189-93
Fisher, S G; Weber, L; Carbone, M (1999) Cancer risk associated with simian virus 40 contaminated polio vaccine. Anticancer Res 19:2173-80
Carbone, M; Fisher, S; Powers, A et al. (1999) New molecular and epidemiological issues in mesothelioma: role of SV40. J Cell Physiol 180:167-72
Rizzo, P; Di Resta, I; Powers, A et al. (1999) Unique strains of SV40 in commercial poliovaccines from 1955 not readily identifiable with current testing for SV40 infection. Cancer Res 59:6103-8

Showing the most recent 10 out of 14 publications